EL7.AI
StocksMediumUpdated•Originally published 16 October 2026•Updated 16 October 2026•
1 min read

City Therapeutics Prices Upsized IPO at $18 Per Share

Key Facts

1RNAi drugmaker City Therapeutics priced its upsized initial public offering at $18 per share.

City Therapeutics, an RNAi drugmaker, priced its upsized initial public offering at $18 per share. Seeking Alpha reported that the biotechnology company, which focuses on RNA interference therapies, increased the offering size to raise capital for its drug development pipeline.

The pricing reached the high end of expectations, signaling strong institutional demand for biotechnology offerings. The company is moving forward with the IPO to capitalize on renewed interest in the sector to fund its specific research in RNAi therapies.

Latest Updates · 1

  1. Notable·

    Update: Reports on October 16, 2026, indicated that City Therapeutics allocated no shares to half of the IPO orders. This move suggests the offering was significantly oversubscribed, reinforcing the strong demand signals observed when the shares were priced at $18.